Stay updated with breaking news from Analytical Reference Standards. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ChromaDex (NASDAQ:CDXC – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Monday. Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of ChromaDex in a research report on Thursday, August 10th. View Our Latest […]
HC Wainwright reaffirmed their buy rating on shares of ChromaDex (NASDAQ:CDXC – Free Report) in a research note published on Thursday morning, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.03 EPS. Other analysts have also recently issued research reports […]
StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC – Free Report) from a buy rating to a strong-buy rating in a report issued on Friday. Other equities research analysts also recently issued research reports about the company. HC Wainwright decreased their target price on ChromaDex from $5.50 to $5.00 and set a buy rating for the company […]
ChromaDex Co. (NASDAQ:CDXC – Get Rating) major shareholder Hoi Shuen Solina Holly Chau acquired 60,037 shares of the stock in a transaction dated Thursday, June 16th. The stock was acquired at an average price of $1.66 per share, for a total transaction of $99,661.42. Following the purchase, the insider now directly owns 6,925,641 shares in […]
IM Cannabis (NASDAQ:IMCC – Get Rating) and ChromaDex (NASDAQ:CDXC – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends. Earnings and Valuation This table compares IM Cannabis and ChromaDex’s […]